NCT06330974

Brief Summary

The summary is available at --\> https://www.finnatopy.fi/summary

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000,000

participants targeted

Target at P75+ for all trials

Timeline
105mo left

Started Oct 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Oct 2024Dec 2034

First Submitted

Initial submission to the registry

March 12, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 26, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
8.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2032

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2034

Last Updated

March 26, 2024

Status Verified

March 1, 2024

Enrollment Period

8.2 years

First QC Date

March 12, 2024

Last Update Submit

March 19, 2024

Conditions

AsthmaAsthma in ChildrenAllergyRhinitis, AllergicAtopic DermatitisAllergen Immunotherapy

Outcome Measures

Primary Outcomes (5)

  • Epidemiology of atopic diseases and allergic sensitization profiles in Finland

    Incidence and prevalence of asthma, specific IgE sensitization, atopic dermatitis, allergic rhinitis

    7 years

  • Burden of atopic diseases (allergies, asthma, and atopic eczema) as well as comorbidities in Finland

    Morbidity, sick leaves, medication use, costs and expences

    7 years

  • Evaluate and improve the current use of diagnostic tests for atopic diseases

    Diagnostic practices, tests for allergic sensitization, lung function tests, and other laboratory measures.

    7 years

  • Use and effectiveness of allergen immunotherapy in real world setting

    Real world evidence data using specific cohorts

    7 years

  • Direct and indirect costs related to atopic diseases and comorbidities

    All costs, including sick leaves, absenteeism, laboratory costs, other diagnisteic tests, etc.

    7 years

Interventions

No interventionOTHER

No intervention

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

https://www.finnatopy.fi/methods

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tampere University

Tampere, Finland

Location

MeSH Terms

Conditions

AsthmaHypersensitivityRhinitis, AllergicDermatitis, Atopic

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateImmune System DiseasesRhinitisNose DiseasesOtorhinolaryngologic DiseasesSkin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Eczematous

Study Officials

  • Péter Csonka

    Tampere University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Péter Csonka, MD, PhD

CONTACT

+358503661103peter.csonka@tuni.fi

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
7 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD, Associate professor of pediatrics

Study Record Dates

First Submitted

March 12, 2024

First Posted

March 26, 2024

Study Start

October 1, 2024

Primary Completion (Estimated)

December 1, 2032

Study Completion (Estimated)

December 1, 2034

Last Updated

March 26, 2024

Record last verified: 2024-03

Locations

FI(1)